Ascendis Pharma A (ASND) Long-Term Deferred Tax (2014 - 2026)

Ascendis Pharma A has reported Long-Term Deferred Tax for 6 years, with the latest figure at $808.3 million in Q1 2026.

• Quarterly Long-Term Deferred Tax changed N/A year-over-year to $808.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $808.3 million (changed N/A YoY) and the FY2025 annual result came in at -$11.2 million, down 44.43% from the prior year.
• Long-Term Deferred Tax grew to $808.3 million in Q1 2026 per ASND's latest filing, from -$11.2 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $808.3 million in Q1 2026 and troughed at -$11.2 million in Q4 2025.
• A 4-year average of $195.8 million and a median of -$7.0 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax decreased 23.64% in 2024, then plunged 44.43% in 2025.
• Over 4 years, Long-Term Deferred Tax stood at -$6.3 million in 2023, then declined by 23.64% to -$7.8 million in 2024, then sank by 44.43% to -$11.2 million in 2025, then surged by 7315.84% to $808.3 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $808.3 million, -$11.2 million, and -$7.8 million for Q1 2026, Q4 2025, and Q4 2024 respectively.